Why Cytokinetics Stock Was a Nearly 5% Winner Today
This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics ...
Cytokinetics stock rises on Sanofi's rights acquisition
Investing.com -- Shares of Cytokinetics (NASDAQ: CYTK ), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ: SNY) will acquire exclusive rights to develop and ...
FierceBiotech2d
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...
Sanofi to acquire rights to develop, commercialize aficamten from Corxel
Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...
Sanofi To Buy Rights To Develop Cytokinetics' Aficamten In Greater China From Corxel
Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major ...
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire ...
Cytokinetics, Incorporated: Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten ...
Hosted on MSN18d
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has ...
thecardiologyadvisor.com19d
Aficamten Under Review for Obstructive Hypertrophic Cardiomyopathy
Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...
Managed Healthcare Executive20d
FDA Sets Goal Date for Cardiomyopathy Drug, Aficamten
The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date has been set for Sept. 26, 2025. Cytokinetics Inc. announced the FDA ...